Skip to main content
Premium Trial:

Request an Annual Quote

Correlia Biosystems Closes $7M Series A Round

NEW YORK – Proteomics firm Correlia Biosystems said on Friday that it has closed a $7 million Series A funding found.

The company said that the round, which was led by Neotribe Ventures and was joined by Cota Capital, the Regents of the University of California, and others, will support the commercial launch of the company's miniaturized ELISA platform.

By miniaturizing ELISA testing, Correlia reduces the time and sample volume required to run these commonly used protein assays.

"With this new funding round, we are poised to bring our unique, more granular assay capabilities to customers who have been waiting for major advances in the 50-year old ELISA market," Correlia CEO Akwasi Apori said in a statement.

"We are excited to join Correlia's journey to create a category-creating new standard for ultra-efficient and highly automated protein biomarker measurement," Swaroop Kolluri, founder and managing director of Neotribe, said in a statement.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.